Reilhac C, Dubourg J, Thang C, Grouin JM, et al. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period. Diabetes Obes Metab 2022 Jan 4. doi: 10.1111/dom.14642.
PMID: 34984815